you might need to do a bit more research. Commodity products don’t often attract 10+ patents - they’re not selling bandaids.
also, they aren’t going to need to / planning to employ a large internal sales force - that’s the reason for the partner agreements.
comment about the valuation is valid, it’s being given a huge valuation relative to its current sales based on potential. Though it’s hardly alone in that regard in this market.
Ann: Next Science Investor Presentation May 2019, page-13
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $58.43M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.0¢ | $21.32K | 107.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NXS (ASX) Chart |